FIELD: chemistry.
SUBSTANCE: invention relates to the polymorphs N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. The invention also relates to a process of preparation of mentioned polymorphs, a pharmaceutical composition comprising mentioned polymorphs, a method for treating a hyperproliferative disease, and the use of mentioned polymorphs. As a result, polymorphic forms of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine having various physical properties in the solid state.
EFFECT: possibility of improving the performance characteristics of the product.
136 cl, 58 dwg, 29 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DISPERSION | 2012 |
|
RU2648448C2 |
| TREATMENT OF BRAIN CANCER | 2013 |
|
RU2672575C2 |
| INHIBITORS OF TYPE ErbB INHIBITORS | 2006 |
|
RU2592703C9 |
| N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
| IMIDAZOLONYLQUINOLINE COMPOUNDS AND THERAPEUTIC USE THEREOF | 2020 |
|
RU2822479C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| CRYSTALLINE TOSYLATE SALT (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8-9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE | 2011 |
|
RU2598606C2 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| NEW CRYSTAL AND AMORPHOUS FORM OF TRYAZOL[4,5-d] PYRIMIDINE | 2001 |
|
RU2325391C2 |
